Gleevec®: Evolving First-Line CML Therapy1,2

• By these parameters measured in the IRIS study, Gleevec offers significant advantages over

IFN-α + low-dose ara-C in patients newly diagnosed with CML.

• Higher rates of progression-free survival, complete cytogenetic response, major cytogenetic

response, and complete hematologic response strongly support the use of Gleevec as front-line

treatment for CML.

• Gleevec also offers a mild to moderate safety and tolerability profile.

References

1. Gleevec® (imatinib mesylate) Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals

Corporation; 2003.

2. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.